Jasmin Mona Klose

Jasmin Mona Klose

Auto-generated profile, based on publicly available information

Jasmin Mona Klose

Klinik für Diabetologie und Endokrinologie, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in eLife
Verified
Journal Article
Open access
ASArne Sahm
Arne Sahm
MPMatthias Platzer
Matthias Platzer
PKPhilipp Koch
Philipp Koch
YHYoshiyuki Henning
Yoshiyuki Henning
MBMartin Bens
Martin Bens
PDPhilip Dammann
Philip Dammann
Sexual activity and/or reproduction are associated with a doubling of life expectancy in the long-lived rodent genusFukomys. To investigate the molecular mechanisms underlying this phenomenon, we analyzed 636 RNA-seq samples across 15 tissues. This analysis suggests that changes in the regulation of the hypothalamic–pituitary–adrenal stress axis play a key role regarding the extended life expectancy of reproductive vs. non-reproductive mole-rats. This is substantiated by a corpus of independent evidence. In accordance with previous studies, the up-regulation of the proteasome and so-called ‘anti-aging molecules’, for example, dehydroepiandrosterone, is linked with enhanced lifespan. On the other hand, several of our results are not consistent with knowledge about aging of short-lived model organisms. For example, we found the up-regulation of the insulin-like growth factor 1/growth hormone axis and several other anabolic processes to be compatible with a considerable lifespan prolongation. These contradictions question the extent to which findings from short-lived species can be transferred to longer-lived ones.

6 January 2022 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
JKJasmin Mona Klose
Jasmin Mona Klose
JWJasmin Wosniack
Jasmin Wosniack
Janette IkingJanette Iking
Janette Iking
MSMagdalena Staniszewska
Magdalena Staniszewska
FZFadi Zarrad
Fadi Zarrad
WFWolfgang Fendler
Wolfgang Fendler
Introduction: The NETTER-1, VISION, and TheraP trials prove efficacy of repeat intravenous (i.v.) application of small radioligands. Application by subcutaneous (s.c.), intraperitoneal (i.p.), or oral (p.o.) access are important alternatives and may yield comparable or favorable organ and tumor radioligand uptake. Here, we assess organ and tumor biodistribution for various radioligand application routes in healthy mice and models of somatostatin receptor (SSTR)-, prostate-specific membrane antigen (PSMA)-, and fibroblast activation protein (FAP)- expressing cancer. Methods: Healthy and tumor-bearing male C57BL/6 or NOD SCID Gamma mice, respectively, were applied with a mean of 6.0±0.5 MBq 68Ga DOTATOC (RM1-SSTR allograft), 5.3±0.3 MBq 68Ga-PSMA11 (RM1-PSMA allograft) or 4.8±0.2 MBq 68Ga-FAPI46 (HT1080 FAP xenograft) i.v., i.p., s.c. or p.o.. In vivo positron emission tomography and ex vivo biodistribution in tumor, organs, and at the injection site were assessed up to 5h post injection (p.i.). Healthy mice were monitored for up to 7 days after the last scan for signs of stress or adverse reactions. Results: After i.v., i.p. and s.c. radioligand administration, average residual activity at the injection site was <17%IA/g (1h p.i.), <10%IA/g (2h p.i.) and ≤4%IA/g (4h p.i.) for all radioligands. Following oral administration ≥50%IA/g remained within the intestines until 4h p.i.. Biodistribution in organs of healthy mice was nearly equivalent following i.v., i.p., and s.c. application at 1h p.i. and all subsequent timepoints (≤1%IA/g for liver, blood and bone marrow; 11.2±1.4%IA/g for kidneys). In models for SSTR-, PSMA- and FAP-expressing cancer, tumor uptake was higher or equivalent for i.p./s.c. versus i.v. injection at 5h p.i. (ex vivo): SSTR: 7.2±1.0%IA/g (P = 0.0197) / 6.5±1.3%IA/g (P = 0.0827) versus 2.9±0.3%IA/g; PSMA: 3.4±0.8%IA/g (P = 0.9954) / 3.9±0.8%IA/g (P = 0.8343) versus 3.3±0.7%IA/g and FAP: 1.1±0.1%IA/g (P = 0.9805) / 1.1±0.1%IA/g (P = 0.7446) versus 1.0±0.2%IA/g. Conclusion: In healthy mice, biodistribution of small theranostic ligands following i.p. or s.c. application is nearly equivalent compared to i.v. injection. S.c. administration resulted in highest absolute SSTR tumor and tumor-to-organ uptake as compared to the i.v. route, warranting further clinical assessment.

13 April 2026 in Diabetologie und Stoffwechsel
Verified
Journal Article
Closed access
SRSusanne Reger-Tan
Susanne Reger-Tan
GFGuido Freckmann
Guido Freckmann
SPStefan Pleus
Stefan Pleus
YHYvonne Häusler
Yvonne Häusler
MNMatthias Nauck
Matthias Nauck
LHLutz Heinemann
Lutz Heinemann
Zusammenfassung: In Gesundheitseinrichtungen ist die Bestimmung der Blutglukose ein zentraler Bestandteil der Überwachung des Gesundheitszustandes, nicht nur zur Diagnostik und Therapie bei Menschen mit Diabetes mellitus, sondern auch in kritischen Situationen wie bspw. auf der Intensivstation. Diese Messungen fallen unter die Qualitätsrichtlinie der Bundesärztekammer (Rili-BÄK) und erfordern geschultes Personal. Systeme zur patient*innennahen Sofortdiagnostik (point of care testing, POCT) ermöglichen Einzelmessung und Befunderhalt vor Ort und damit unmittelbare therapeutische Intervention. Neben der Präzision und Messqualität sind Aspekte wie die sichere Identifikation der Patient*innen und Anwendenden, die digitale Anbindung an Middleware, Laborinformations- oder Krankenhausinformationssystem sowie die Dokumentation der Qualitätskontrolle entscheidend. Digitale Lösungen bieten Vorteile: automatisierte Datenübermittlung, Steigerung der Dokumentationsrate und Reduktion von Fehlerquellen. Die Verantwortung für Qualitätssicherung und Schulung sollte idealerweise beim Zentrallabor liegen. Implementations-Hürden bestehen insbesondere in der heterogenen Systemlandschaft und Fehlen strukturierter Informationen über verfügbare POCT-Systeme für Gesundheitseinrichtungen. Einflussfaktoren wie Hämatokrit oder interferierende Substanzen können das Messergebnis verfälschen. Investitions- und Betriebskosten, Datenschutz und Interoperabilität, aber auch das Potenzial innovativer digitaler Technologien wie kontinuierliches Glukosemonitoring (CGM), automatisierte Insulinpumpensysteme (AID) und (KI-basierte) Entscheidungsunterstützungssysteme in der Krankenhausversorgung beeinflussen die Wahl für ein bestimmtes System. Dieser Beitrag soll Gesundheitsinstitutionen in einer kurzen Übersicht über derzeit verfügbare POCT-Systeme informieren.